Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. [electronic resource]
Producer: 20190830Description: 122 p. digitalISSN:- 1471-2407
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biosimilar Pharmaceuticals -- administration & dosage
- Breast Neoplasms -- drug therapy
- Docetaxel -- administration & dosage
- Double-Blind Method
- Doxorubicin -- administration & dosage
- Female
- Filgrastim -- administration & dosage
- Hematologic Agents -- administration & dosage
- Humans
- Middle Aged
- Neoplasm Staging
- Neutropenia -- chemically induced
- Polyethylene Glycols -- administration & dosage
- Therapeutic Equivalency
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.